Reply to Kulić, Ž. Comment on "Subhadra et al. Significant Broad-Spectrum Antiviral Activity of Bi121 against Different Variants of SARS-CoV-2. Viruses 2023, 15, 1299"

Viruses. 2023 Nov 17;15(11):2269. doi: 10.3390/v15112269.

Authors

Bobban Subhadra¹, Ragini Agrawal², Virender Kumar Pal², Agnes-Laurence Chenine³, Jeffy George Mattathil³, Amit Singh²

Affiliations

¹ Biom Pharmaceutical Corporation, 2203 Industrial Blvd, Sarasota, FL 34234, USA.
² Department of Microbiology and Cell Biology, Center for Infectious Disease Research, Indian Institute of Science (IISc), CV Raman Ave., Bengaluru 560012, India.
³ Integrated BioTherapeutics Inc., 4 Research Court, Suite 300, Rockville, MD 20850, USA.

Abstract

We would like to thank Dr. Žarko Kulić [...].

MeSH terms

Antiviral Agents / pharmacology
COVID-19*
Humans
SARS-CoV-2 / genetics

Substances

Antiviral Agents

Grants and funding

Biom Pharmaceutical Corporation funded this research (Grant #BR2021-12c).